FDA Issues Draft Guidance on Rare Diseases
The agency revised draft guidance to enable more efficient and successful drug development programs for the treatment or prevention of rare diseases.
On Jan. 17, 2019, FDA announced that it issued a revised draft guidance to enable more efficient and successful drug development programs for the treatment or prevention of rare diseases.
The draft guidance, Rare Diseases: Common Issues in Drug Development Guidance for Industry, was originally issued in 2015. The revised guidance covers a range of topics such as natural history studies, use of biomarkers, and methods for demonstrating effectiveness and safety.
Comments and suggestions should be submitted within 60 days of publication.
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
